Skip Navigation


JAC Advance Access originally published online on October 22, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/5/621    most recent
dkf244v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johnson, A. P.
Right arrow Articles by Woodford, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, A. P.
Right arrow Articles by Woodford, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 621-623
© 2002 The British Society for Antimicrobial Chemotherapy

Leading articles

Glycopeptide-resistant Staphylococcus aureus

Alan P. Johnson* and Neil Woodford

Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London NW9 5HT, UK

Keywords: Staphylococcus aureus, glycopeptides, resistance

The first 10% of the full text of this article appears below.

Fourteen years ago, two near-simultaneous reports documented the emergence of enterococci with high-level resistance to vancomycin and teicoplanin.1,2 These reports featured a cluster of isolates from a single hospital in London and isolates from two patients in France, but over the next decade, glycopeptide-resistant enterococci (GRE) were isolated from many countries worldwide, and are now a major problem, particularly in North America. The recent report of the isolation of a fully glycopeptide-resistant Staphylococcus aureus (GRSA; vancomycin MIC > 128 mg/L; teicoplanin MIC 32 mg/L),3 in Michigan, USA, therefore begs the question: ‘Will history repeat itself?’ Are we just looking at an interesting isolate from a single patient, or is it the forerunner of a potentially major crisis in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. L. Embleton, S. P. Nair, W. Heywood, D. C. Menon, B. D. Cookson, and M. Wilson
Development of a Novel Targeting System for Lethal Photosensitization of Antibiotic-Resistant Strains of Staphylococcus aureus
Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3690 - 3696.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Casewell, C. Friis, E. Marco, P. McMullin, and I. Phillips
The European ban on growth-promoting antibiotics and emerging consequences for human and animal health
J. Antimicrob. Chemother., August 1, 2003; 52(2): 159 - 161.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Vaudaux, P. Francois, C. Bisognano, D. Li, D. P. Lew, and J. Schrenzel
Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus
J. Antimicrob. Chemother., July 1, 2003; 52(1): 89 - 95.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. J. Dancer
Glycopeptide resistance in Staphylococcus aureus
J. Antimicrob. Chemother., May 1, 2003; 51(5): 1309 - 1311.
[Full Text] [PDF]